Skip to Content

Final analysis of TITAN confirms survival benefit of apalutamide for metastatic castration-sensitive prostate cancer

The final analysis of the TITAN study establishes that adding apalutamide to ADT in patients with metastatic castration-sensitive prostate cancer (mCSPC) leads to significantly improved survival and a consistent side effect profile for the intervention arm

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top